|   DPT-IPV vaccine in Japan | |
| Combination of | |
|---|---|
| DTaP vaccine | Vaccine | 
| Inactivated poliovirus vaccine | Vaccine | 
| Clinical data | |
| Trade names | Kinrix, Quadracel, Boostrix-IPV, Infanrix-IPV, others | 
| Other names | diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) | 
| AHFS/Drugs.com | Kinrix Quadracel | 
| Pregnancy category | 
 | 
| Routes of administration | Intramuscular injection | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| CAS Number | |
DTaP-IPV vaccine is a combination vaccine whose full generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine (IPV). [1] [2]
It is also known as DTaP/IPV, dTaP/IPV, DTPa-IPV, or DPT-IPV. [1] It protects against the infectious diseases diphtheria, tetanus, pertussis, and poliomyelitis. [1]
Branded formulations marketed in the USA are Kinrix from GlaxoSmithKline [3] and Quadracel from Sanofi Pasteur. [4]
Repevax is available in the UK. [5] [6]
In Japan, the formulation is called 四種混合(shishukongou - "mixture of 4"). Astellas markets it under the クアトロバック ('Quattro-back') formulation, while another is available from Mitsubishi Tanabe Pharma named テトラビック ('Tetrabic'). [7] [8] A previous product by Takeda Pharmaceutical Company has been withdrawn by the company. [9]